Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585296 · ClinicalTrials.gov registry record · Phase 2
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03585296 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 22 participants.
The verdict
NCT03585296, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD). Subjects will be required to apply ATI-502 study medication to their identified AD treatment areas. All subjects will be required to complete a safety follow up visit 4 weeks post last study medication application
Interventions
- DRUG ATI-502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2019-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03585296
The ClinicalTrials.gov registry entry for NCT03585296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATI-502 is the first listed.
NCT03585296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03585296 about?
NCT03585296 is a clinical study titled "A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis". This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD). Subjects will be required to apply ATI-502 study medication to their identified AD treatment areas. All su...
What is the current status of trial NCT03585296?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2018-07-10. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT03585296?
The interventions under investigation include: ATI-502 (DRUG).
Who is sponsoring clinical trial NCT03585296?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.